fosamprenavir News - LARVOL Sigma

12 »

|||||||||| Aptivus (tipranavir) / Boehringer Ingelheim
PK/PD data, Review, Journal: Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV, Part II: Drugs Licensed Before 2005. (Pubmed Central) - Dec 16, 2024
Exposure to 3TC, TDF, FTC, ATV, LPV, and RTV increases with age, while exposure to ABC and EFV appears to be unaffected. Despite the large quantity of data on PK in young adults, there is still a gap in knowledge about the effects of aging on the PK of these ARVs.

||||||||||  fosamprenavir / Generic mfg.
New P2 trial:  Oral Fosamprenavir + Sodium Alginate for GERD (clinicaltrials.gov) -  Nov 25, 2024
P2, N=60, Not yet recruiting,  Sponsor: Medical College of Wisconsin

|||||||||| fosamprenavir / Generic mfg.
Review, Journal: Advances in laryngopharyngeal reflux: Etiology, diagnosis, and management. (Pubmed Central) - Nov 21, 2024
Laryngeal hypersensitivity should be considered as part of a comprehensive therapeutic approach. Promising medical and scientific research continues to yield new insights into the complex etiology of LPR and novel strategies for its diagnosis and management.

|||||||||| fosamprenavir / Generic mfg.
Journal: Study APV20002: Safety and Efficacy Results Through Week 684 for Pediatric Participants Living With HIV-1 Treated With Ritonavir-Boosted Fosamprenavir Oral Solution-Based Antiretroviral Therapy. (Pubmed Central) - Oct 8, 2024
Post-48W, 4/5 participants with VF had phenotype results; all were still susceptible to all study drugs at VF. In conclusion, FPV OS-based ART was efficacious and generally well tolerated in this long-running pediatric study through 684 weeks of treatment, with a safety profile consistent with experience in adults and older children.

|||||||||| Aptivus (tipranavir) / Boehringer Ingelheim, Edurant (rilpivirine) / J&J, Viracept (nelfinavir) / ViiV Healthcare, Roche
Journal: Pretreatment drug resistance among people living with HIV from 2018 to 2022 in Guangzhou, China. (Pubmed Central) - Sep 26, 2024
Among PI, resistance to tipranavir (0.8%), nelfinavir (0.6%), fosamprenavir (0.2%) and lopinavir (0.1%) was most frequent...The overall prevalence of PDR in Guangzhou was moderate, with relatively severe NNRTI resistance. Therefore, it remains crucial to continue monitoring PDR among newly diagnosed HIV-infected individuals.

||||||||||  fosamprenavir / Generic mfg.
Phase classification, Trial completion date, Trial primary completion date:  Oral Fosamprenavir-Sodium Alginate for LPR (clinicaltrials.gov) -  Aug 1, 2024
P2, N=104, Not yet recruiting,  Sponsor: Medical College of Wisconsin
Therefore, it remains crucial to continue monitoring PDR among newly diagnosed HIV-infected individuals. Phase classification: P3 --> P2 | Trial completion date: Oct 2025 --> Apr 2026 | Trial primary completion date: Oct 2025 --> Feb 2026

||||||||||  fosamprenavir / Generic mfg.
Trial completion date, Trial primary completion date:  Oral Fosamprenavir-Sodium Alginate for LPR (clinicaltrials.gov) -  Mar 12, 2024
P3, N=104, Not yet recruiting,  Sponsor: Medical College of Wisconsin
Phase classification: P3 --> P2 | Trial completion date: Oct 2025 --> Apr 2026 | Trial primary completion date: Oct 2025 --> Feb 2026 Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025

|||||||||| fosamprenavir / Generic mfg.
Journal: Inhaled fosamprenavir for laryngopharyngeal reflux: Toxicology and fluid dynamics modeling. (Pubmed Central) - Feb 16, 2024
A formal GLP assessment is underway to support a phase I clinical trial of an FOS DPI for LPR. NA.

|||||||||| fosamprenavir / Generic mfg.
Journal: Development and Evaluation of a Protease Inhibitor Antiretroviral Drug-Loaded Carbon Nanotube Delivery System for Enhanced Efficacy in HIV Treatment. (Pubmed Central) - Jan 8, 2024
To achieve this, Fosamprenavir calcium (FPV), a prodrug of amprenavir known for inhibiting the proteolytic cleavage of immature virions, was selected as the protease inhibitor antiretroviral drug, and loaded onto COOH-MWCNTs using a direct loading method...The successful encapsulation, sustained drug release, and reduced toxicity make FPV-MWCNT a compelling candidate for enhancing the therapeutic efficacy of protease inhibitor antiretroviral drugs in the treatment of HIV. The developed delivery system holds great promise for future advancements in HIV treatment and paves the way for further research and development in the field of drug delivery utilizing carbon nanotube-based systems.

||||||||||  fosamprenavir / Generic mfg.
Trial completion:  Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects (clinicaltrials.gov) -  Oct 10, 2023
P2, N=59, Completed,  Sponsor: ViiV Healthcare
The developed delivery system holds great promise for future advancements in HIV treatment and paves the way for further research and development in the field of drug delivery utilizing carbon nanotube-based systems. Unknown status --> Completed

|||||||||| amprenavir / Generic mfg.
Preclinical, Journal: Amprenavir inhibits pepsin-mediated laryngeal epithelial disruption and E-cadherin cleavage in vitro. (Pubmed Central) - Aug 25, 2023
Amprenavir, at serum concentrations achievable provided the manufacturer's recommended dose of fosamprenavir for HIV, protects against pepsin-mediated cell dissociation, E-cadherin cleavage, and MMP dysregulation thought to contribute to barrier dysfunction and related symptoms during LPR. Fosamprenavir to amprenavir conversion by laryngeal epithelia, serum and saliva, and relative drug efficacies in an LPR mouse model are under investigation to inform development of inhaled formulations for LPR.

|||||||||| Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Rescriptor (delavirdine mesylate) / ViiV Healthcare, Relenza (zanamivir) / GSK, Vaxart
FDA event, Journal: Drug repurposing of FDA-approved anti-viral drugs via computational screening against novel 6M03 SARS-COVID-19. (Pubmed Central) - Jul 29, 2023
Fosamprenavir to amprenavir conversion by laryngeal epithelia, serum and saliva, and relative drug efficacies in an LPR mouse model are under investigation to inform development of inhaled formulations for LPR. In our study, we also observed the nucleotide sequence of protease protein consisting of 316 amino acid residues

||||||||||  fosamprenavir / Generic mfg.
Trial primary completion date:  Oral Fosamprenavir-Sodium Alginate for LPR (clinicaltrials.gov) -  Jun 28, 2023
P3, N=104, Not yet recruiting,  Sponsor: Medical College of Wisconsin
In our study, we also observed the nucleotide sequence of protease protein consisting of 316 amino acid residues Trial primary completion date: Jun 2024 --> Oct 2024

|||||||||| Rukobia (fostemsavir) / ViiV Healthcare, fosamprenavir / Generic mfg.
Journal: Validation of an LC-MS/MS method for quantitation of fostemsavir in plasma. (Pubmed Central) - Mar 16, 2023
Trial primary completion date: Jun 2024 --> Oct 2024 In summary, the developed method has been successfully validated and pharmacokinetic parameters were demonstrated after oral administration of Fostemsavir to healthy rabbits.

||||||||||  fosamprenavir / Generic mfg.
Trial completion date, Trial primary completion date:  Oral Fosamprenavir-Sodium Alginate for LPR (clinicaltrials.gov) -  Mar 14, 2023
P3, N=104, Not yet recruiting,  Sponsor: Medical College of Wisconsin
In summary, the developed method has been successfully validated and pharmacokinetic parameters were demonstrated after oral administration of Fostemsavir to healthy rabbits. Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Jan 2024 --> Jun 2024

|||||||||| fosamprenavir / Generic mfg.
Preclinical, Journal: In-vitro Dynamic Dissolution/Bioconversion/Permeation of Fosamprenavir using a Novel Tool with an Artificial Biomimetic Permeation Barrier and Microdialysis-Sampling. (Pubmed Central) - Dec 25, 2022
At conditions with an almost 10-fold higher dose than the usual human dose, some replicates showed premature precipitation and collapse of supersaturation, while others did not. In conclusion, the proposed novel tool appears very promising in gaining an in-depth mechanistic understanding of the bioconversion/permeation interplay, including transient supersaturation of phosphate-ester prodrugs like fosamprenavir.

|||||||||| Review, Journal: Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses. (Pubmed Central) - Nov 2, 2022
Didanosine, zalcitabine, zidovudine, efavirenz, amprenavir, fosamprenavir, and indinavir should be taken on an empty stomach for maximum patient benefit...There is insufficient evidence available to make recommendations about consuming juice or alcohol with antiretroviral drugs. Resolving drug-food interactions may contribute to maximized cART effectiveness and safety.

|||||||||| Journal: Discovery of Novel HIV Protease Inhibitors Using Modern Computational Techniques. (Pubmed Central) - Oct 28, 2022
HPS/002 and HPS/004 have been found to be most promising in terms of IC/percent inhibition (90.15%) of HIV-1 PR, in addition to their drug metabolism and safety profile. These hit candidates should be investigated further as possible HIV-1 PIs with improved efficacy and low toxicity through in vitro experiments and clinical trial investigations.

|||||||||| fosamprenavir / Generic mfg.
Journal: A New, Rapid and Simple RP-HPLC Method for Stability Quantification of a Protease Inhibitor in Tablets. (Pubmed Central) - Sep 10, 2022
The analyte peak was found to be adequately separated from degradation products generated during forced degradation studies. Thus, the proposed method was found to accurately indicate stability and was sufficient for routine quantitative analysis of fosamprenavir in coated tablets without interference from major degradation products and excipients.

|||||||||| Prezista (darunavir) / J&J
Journal: Impact of age and gender disparity on CD4+ cell counts to control disease progression using specific HAART in HIV-1 positive patients: A case-control study. (Pubmed Central) - Aug 22, 2022
Thus, the proposed method was found to accurately indicate stability and was sufficient for routine quantitative analysis of fosamprenavir in coated tablets without interference from major degradation products and excipients. The administration of specific HAART (NRTIs and novel protease inhibitors) in HIV patients had a notable improvement in the CD4+ cell count and viral load with significant age and gender disparity.

|||||||||| fosamprenavir / Generic mfg.
Preclinical, Journal: Oral and Inhaled Fosamprenavir Reverses Pepsin-Induced Damaged in a Laryngopharyngeal Reflux Mouse Model. (Pubmed Central) - Jun 10, 2022
These drugs target a foreign virus, making them ideal to repurpose. Reformulation for local inhaled delivery could further improve outcomes and limit side effects.

|||||||||| zidovudine / Generic mfg.
PK/PD data, Review, Journal: A Review on Pharmacokinetics properties of antiretroviral drugs to treat HIV-1 infections. (Pubmed Central) - Jan 18, 2022
These drugs are Fuzeon, Selzentry, Complera, Epivir, Retrovir, Emtriva, Ziagen, Edurant, Intelence, Pifeltro, Sustiva, Viramune, Isentress, Genvoya, Tivicay, Reyataz, Prezista, Lexiva, Invirase, Aptivus etc. classified into five major classes: fusion inhibitors, Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Integrase Strand transfer inhibitors (INSTIs) and Protease inhibitors (PIs). This review may be helpful for the future development of potent antiretroviral drugs with improved pharmacokinetic properties.

||||||||||  fosamprenavir / Generic mfg.
Trial completion date, Trial primary completion date:  Oral Fosamprenavir-Sodium Alginate for LPR (clinicaltrials.gov) -  Nov 22, 2021
P3, N=104, Not yet recruiting,  Sponsor: Medical College of Wisconsin
This review may be helpful for the future development of potent antiretroviral drugs with improved pharmacokinetic properties. Trial completion date: Jun 2024 --> Mar 2024 | Trial primary completion date: Jun 2024 --> Jan 2024

|||||||||| Prezista (darunavir) / J&J, Crixivan (indinavir sulfate) / Merck (MSD)
Retrospective data, Review, Journal: HIV Protease Inhibitors and Insulin Sensitivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - Nov 21, 2021
Darunavir and indinavir did not demonstrate any significant changes in insulin sensitivity...Atazanavir, fosamprenavir, and darunavir did not demonstrate any significant changes in insulin sensitivity, compared to the rest of the group...All patients newly diagnosed with HIV should have DM investigations before the start of ARVs and routinely. RCTs should focus on sub-Saharan Africa as the region is worst affected by HIV, but limited studies have been documented.

|||||||||| hydroxychloroquine / Generic mfg.
Journal: Identification of potential natural inhibitors of the receptor-binding domain of the SARS-CoV-2 spike protein using a computational docking approach. (Pubmed Central) - Oct 5, 2021
Using computational screening, we identified potential SARS-CoV-2 S glycoprotein inhibitors that bind to the RBD region. Using structure-based design and combination-based drug therapy, the identified molecules could be used to generate anti-SARS-CoV-2 drug candidates.

|||||||||| eplerenone / Generic mfg.
Clinical, Journal: Severe hyperkalaemia due to a potential drug-drug interaction between eplerenone and antiretrovirals in a HIV-positive patient after a myocardial infarction. (Pubmed Central) - Sep 22, 2021
Eplerenone is metabolized by the hepatic P450 cytochrome isoenzyme CYP3A4; therefore, concomitant administration with CYP3A4 inhibitors, like ritonavir, may increase plasma levels of eplerenone and, therefore, the risk of side effects, mainly hyperkalaemia. Based on this case, it is important to alert the medical community of this possible life-threatening drug-drug interaction between eplerenone and ritonavir-boosted protease inhibitor.

|||||||||| Phase classification: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Jun 10, 2021
P=N/A, N=1578, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Based on this case, it is important to alert the medical community of this possible life-threatening drug-drug interaction between eplerenone and ritonavir-boosted protease inhibitor. Phase classification: P4 --> P=N/A

||||||||||  fosamprenavir / Generic mfg.
Trial completion date, Trial primary completion date:  Oral Fosamprenavir-Sodium Alginate for LPR (clinicaltrials.gov) -  May 10, 2021
P3, N=104, Not yet recruiting,  Sponsor: Medical College of Wisconsin
Phase classification: P4 --> P=N/A Trial completion date: Nov 2025 --> Jun 2024 | Trial primary completion date: Nov 2025 --> Jun 2024

|||||||||| fosamprenavir / Generic mfg.
PK/PD data, Journal: Fosamprenavir with Ritonavir Pharmacokinetics During Pregnancy. (Pubmed Central) - Feb 23, 2021
Amprenavir area under the curve exceeded the target for 6/8 (75%) in the 2 trimester; 18/28 (64%) in the 3 trimester; and 19/22 (86.4%) postpartum, and the trough concentrations (C) of amprevavir were 4-16 fold above the mean amprenavir-protein-adjusted IC of 0.146μg/mL. Although amprenavir plasma concentrations in women receiving ritonavir-boosted fosamprenavir were lower during pregnancy compared to postpartum, the reduced amprenavir concentrations were still above the exposures needed for viral suppression.

|||||||||| Vistide (cidofovir) / Gilead
Journal: Identification of potential antivirals against SARS-CoV-2 using virtual screening method. (Pubmed Central) - Feb 18, 2021
Furthermore, some approved structural analogues, such as Telbivudine, Tenofovir, Amprenavir, Fosamprenavir, etc., were predicted as similar drugs which may also be used for treating viral infections. We highly recommend these drug candidates as potential fighters against the deadly SARS-CoV-2 virus, and suggest in vivo trials for experimental validation of our findings.

|||||||||| fosamprenavir / Generic mfg.
Clinical, P4 data, Journal: Safety analysis of Lexiva Tablets 700 (fosamprenavir calcium hydrate) in post-marketing surveillance in Japan. (Pubmed Central) - Dec 18, 2020
Of 364 patients receiving fosamprenavir, 51% received emtricitabine/tenofovir disoproxil fumarate. The results of this PMS analysis in Japan support its known safety profile and identified no new safety risks for people living with HIV/AIDS in Japan currently on, or beginning treatment with, fosamprenavir.

|||||||||| Sovaldi (sofosbuvir) / Gilead
Journal: MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs. (Pubmed Central) - Oct 23, 2020
In addition, another 10 compounds from CAS COVID-19 antiviral candidate compounds dataset are also suggested by Molecular Complex Characterizing System with potential treatment for COVID-19. Our work provides a novel strategy for the repurposing and combinations of drugs in the market and for prediction of chemical candidates with anti-COVID-19 potential.

|||||||||| Trial completion: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Oct 13, 2020
P4, N=1578, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Our work provides a novel strategy for the repurposing and combinations of drugs in the market and for prediction of chemical candidates with anti-COVID-19 potential. Active, not recruiting --> Completed

|||||||||| Journal: Computational Evaluation of the Inhibition Efficacies of HIV Antivirals on SARS-CoV-2 (COVID-19) Protease and Identification of 3D Pharmacophore and Hit Compounds. (Pubmed Central) - Oct 7, 2020
All other derived molecules obeyed the Lipinski rule. In vitro, in vivo, and toxicological studies of these compounds have to be performed before checking the actual druggability of these compounds.

|||||||||| fosamprenavir / Generic mfg.
It really would be more fun if it included the fosamprenavirs of the world too (Twitter) - Oct 1, 2020

|||||||||| ritonavir / Generic mfg., lamivudine / Generic mfg.
Clinical, Journal: Hypersensitivity pneumonia and HIV infection in occupational settings: a case report from northern Italy. (Pubmed Central) - Sep 1, 2020
At age 32, HIV positivity was diagnosed, with HAART starting only at age 38 (initially, lamivudine 300 mg/daily + zidovudine 300 mg b.i.d.). In the following 15 years, CD4+ count remained 95%: CD4+ count remained >600 cells/µL with CD8+ count steadily 55%).

|||||||||| Jakafi oral (ruxolitinib) / Novartis, Incyte, emricasan (IDN 6556) / Conatus, Novartis, fosamprenavir / Generic mfg.
Clinical, Journal: Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19). (Pubmed Central) - Jul 22, 2020
In the following 15 years, CD4+ count remained 95%: CD4+ count remained >600 cells/µL with CD8+ count steadily 55%). While these findings are not yet ready for clinical translation, this report highlights the potential use of two bioinformatics technologies to rapidly discover existing therapeutic agents that warrant further investigation for established and emerging disease processes.

|||||||||| fosamprenavir / Generic mfg.
Journal: Studies on the characterization and polymorphic stability of Fosamprenavir. (Pubmed Central) - Jun 14, 2020
In studies of accelerated stability the techniques of DSC, PXRD and FTIR showed that Form I does not suffer phase change when submitted to controlled conditions of temperature and humidity. Moreover, HPLC and FTIR proved the chemical stability of this solid form of fosamprenavir, thus demonstrating its suitability for pharmaceutical purposes.

|||||||||| fosamprenavir / Generic mfg.
Journal: The influence of gastric motility on the intraluminal behavior of fosamprenavir. (Pubmed Central) - Jun 4, 2020
Mean plasma t values were 157 (± 72.0) and 73.3 (± 27.3) min after administration in MMC phase I and MMC phase II, respectively. The study clearly identified the time of oral drug intake relative to the interdigestive motility pattern as a possible source of variation in gastrointestinal drug behavior and absorption.

||||||||||  fosamprenavir / Generic mfg.
New P3 trial:  Oral Fosamprenavir-Sodium Alginate for LPR (clinicaltrials.gov) -  May 11, 2020
P3, N=104, Not yet recruiting,  Sponsor: Medical College of Wisconsin

|||||||||| Enrollment closed: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Jan 14, 2020
P4, N=1786, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
The study clearly identified the time of oral drug intake relative to the interdigestive motility pattern as a possible source of variation in gastrointestinal drug behavior and absorption. Recruiting --> Active, not recruiting

|||||||||| fosamprenavir / Generic Mfg.
Journal: Stability behaviour of antiretroviral drugs and their combinations. 10: LC-HRMS, LC-MS, LC-NMR and NMR characterization of fosamprenavir degradation products and in silico determination of their ADMET properties. (Pubmed Central) - Nov 29, 2019
The collated information was helpful in characterization of all the DPs, and to delineate the degradation pathway of the drug. Additionally, physicochemical, as well as absorption, distribution, metabolism, excretion and toxicity (ADMET) properties of the drug and its DPs were evaluated in silico by ADMET Predictor software.

|||||||||| Ziagen (abacavir) / ViiV Healthcare
Journal: Effects of antiretroviral treatment and nadir CD4 count in progression to cardiovascular events and related comorbidities in a HIV Brazilian cohort: a multi-stage approach. (Pubmed Central) - May 30, 2019
This analysis suggests that prolonged use of certain antiretroviral drugs led directly to major cardiovascular events, while low nadir CD4 only affected the occurrence of lipid abnormalities and hypertension. Management strategies, including rational use of complex exams (such as, computed-tomography angiography), statins and antihypertensives, should be developed based on the distinct roles of antiretroviral use and of HIV infection itself on the progression to cardiovascular events.

|||||||||| Trial completion date, Trial primary completion date: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - May 20, 2019
P4, N=1786, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Management strategies, including rational use of complex exams (such as, computed-tomography angiography), statins and antihypertensives, should be developed based on the distinct roles of antiretroviral use and of HIV infection itself on the progression to cardiovascular events. Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Jun 2019 --> Sep 2020

|||||||||| Trial completion: TRULIGHT: Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (clinicaltrials.gov) - Dec 4, 2018
P3, N=224, Completed, Sponsor: University Hospital, Tours
Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Jun 2019 --> Sep 2020 Active, not recruiting --> Completed

|||||||||| Trial primary completion date: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - May 2, 2018
P4, N=1786, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Trial primary completion date: Mar 2018 --> Jun 2019

|||||||||| Trial primary completion date: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Oct 7, 2017
P4, N=1786, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Mar 2018 --> Jun 2019 Trial primary completion date: Jun 2019 --> Mar 2018

|||||||||| Enrollment closed: TRULIGHT: Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (clinicaltrials.gov) - Oct 6, 2017
P3, N=224, Active, not recruiting, Sponsor: University Hospital, Tours
Trial primary completion date: Jun 2019 --> Mar 2018 Recruiting --> Active, not recruiting

||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
Trial completion:  HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen (clinicaltrials.gov) -  Jun 14, 2017
P4, N=44, Completed,  Sponsor: Hospital Universitari Vall d'Hebron Research Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  fosamprenavir / Generic mfg.
Phase classification:  Fosamprenavir Versus Other Protease Inhibitors (clinicaltrials.gov) -  Jun 9, 2017
P3b/4, N=312, Completed,  Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Phase classification: P3 --> P3b/4



	Diseases Companies Products Productz Mechanisms of Action Sites